Fundraising Fox
🦊/People
Sign in

Yael Weiss

Founder

Founder at Mahzi Therapeutics

Evanston, Illinois, United States

FoundedMahzi Therapeutics

Find your path to Yael

136 people in our graph share verified history with Yael — schools, employers, funds. One of them is your warm intro.

Alan WaltsunlockedYael: together at Genzyme (2001–2003)
×6Yael: together at Genzyme
Yael: together at Ultragenyx Pharmaceutical Inc.
×4Yael: together at Weizmann Institute of Science

About

Yael Weiss is the founder and Chief Executive Officer of Mahzi Therapeutics, which she established in 2021 to develop therapies for rare neurogenetic diseases in partnership with patient advocacy organizations. The company is currently dosing patients in a gene therapy trial for Pitt Hopkins syndrome, developed with the Pitt Hopkins Research Foundation. Weiss holds an MD from Hebrew University/Hadassah and a PhD from the Weizmann Institute, previously worked at Genzyme, Merck, and Ultragenyx, and is a 2022 Termeer Fellow and a member of the NIH Bespoke Gene Therapy Consortium and the ASGCT translational committee.

Founder at Mahzi Therapeutics

Intro paths

→

In turn, Yael can intro founders to Mahzi Therapeutics's investors below.

Mahzi Therapeutics's investors · 5

Droia VenturesLeuven · $540K checksHealthCapStockholmMitsui Global InvestmentMenlo Park · $500K – $10M checksVenrockPalo Alto · $500K – $10M checksVenrock AssociatesPalo Alto · since 2021

Experience

  1. Mahzi TherapeuticsChief Executive Officercurrent2021 — present
  2. SPARK NSMember TRAC committeecurrent2026 — presentMenlo Park, CA
  3. Biotech CEO SisterhoodMembercurrent2023 — present
  4. Ultragenyx Pharmaceutical Inc.VP Business Development2017 — 2022
  5. Ultragenyx Pharmaceutical Inc.Executive Director, Search and Evaluation, Business Development2014 — 2022Novato, California
  6. MerckExecutive Director, Head MRL regional deals2011 — 2014
  7. MerckDirector, Global Scientific Affairs2007 — 2011
  8. Merck Sharp & DohmeMedical Director2003 — 2007
  9. GenzymeMedical Director2000 — 2003
  10. Columbine VenturesVP1999 — 2002

Skills & more

Clinical Development67Biotechnology80Clinical Trials34Drug Development78Oncology21Lifesciences8Drug Discovery34Immunology16Infectious Diseases8Biopharmaceuticals23Technology Transfer18Medical Devices11
+11 moreVaccinesClinical ResearchNeurosciencePharmacologyMolecular BiologyBiomarkersR&DFDAPharmaceutical IndustryCROTeam Management

From Yael's professional profile.

Frequently asked questions

Who is Yael Weiss?
Yael Weiss is the founder and Chief Executive Officer of Mahzi Therapeutics, which she established in 2021 to develop therapies for rare neurogenetic diseases in partnership with patient advocacy organizations. The company is currently dosing patients in a gene therapy trial for Pitt Hopkins syndrome, developed with the Pitt Hopkins Research Foundation. Weiss holds an MD from Hebrew University/Hadassah and a PhD from the Weizmann Institute, previously worked at Genzyme, Merck, and Ultragenyx, and is a 2022 Termeer Fellow and a member of the NIH Bespoke Gene Therapy Consortium and the ASGCT translational committee.
Where does Yael Weiss work?
Yael Weiss is Founder of Mahzi Therapeutics.
What companies did Yael Weiss found?
Yael Weiss founded Mahzi Therapeutics.
Where did Yael Weiss go to school?
Yael Weiss studied at Weizmann Institute of Science (MSc, PhD); The Hebrew University of Jerusalem (Doctor of Medicine (MD)); Tel Aviv University (BSc, Biology).

Founder mafias

Same school

Shared employers